In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with ...

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynecological Oncological ...

For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated ...

Matulonis, MD, discusses preliminary efficacy and safety results for puxitatug samrotecan in patients with recurrent endometrial cancer ... had received prior immunotherapy,” Matulonis, chief ...

In endometrial cancer, it’s not yet clear what the clinical ... adding PARP inhibitors to immunotherapy and the DUO- E trial results, where numerically, the outcomes look better with that ...

An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.

Immunotherapy drugs like dostarlimab have been used as a front-line treatment for some metastatic cancers, melanoma, and other cancer types. Dostarlimab was first approved for use in endometrial ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Imfinzi be used in combination with ...

Overnight, I became what’s known in the medical system as an “AYA,” an acronym that stands for an adolescent or younger adult ...